IQVIA Holdings Inc. $IQV Shares Purchased by Pinkerton Wealth LLC

Pinkerton Wealth LLC raised its position in IQVIA Holdings Inc. (NYSE:IQV) by 27.8% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 21,443 shares of the medical research company’s stock after purchasing an additional 4,659 shares during the period. Pinkerton Wealth LLC’s holdings in IQVIA were worth $4,073,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Alliancebernstein L.P. lifted its stake in shares of IQVIA by 0.6% in the second quarter. Alliancebernstein L.P. now owns 3,555,929 shares of the medical research company’s stock worth $560,379,000 after buying an additional 19,573 shares in the last quarter. Artisan Partners Limited Partnership grew its stake in IQVIA by 4.9% during the 3rd quarter. Artisan Partners Limited Partnership now owns 3,433,957 shares of the medical research company’s stock valued at $652,246,000 after acquiring an additional 161,085 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in IQVIA by 22.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,126,171 shares of the medical research company’s stock valued at $492,659,000 after acquiring an additional 581,157 shares during the last quarter. Nordea Investment Management AB lifted its stake in IQVIA by 12.3% in the 3rd quarter. Nordea Investment Management AB now owns 2,314,219 shares of the medical research company’s stock worth $421,257,000 after purchasing an additional 253,759 shares in the last quarter. Finally, Cantillon Capital Management LLC boosted its holdings in shares of IQVIA by 27.3% during the 3rd quarter. Cantillon Capital Management LLC now owns 1,926,934 shares of the medical research company’s stock worth $366,002,000 after purchasing an additional 413,256 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Barclays upgraded IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price target for the company in a research report on Friday. BMO Capital Markets set a $250.00 price objective on IQVIA in a research note on Friday, February 6th. JPMorgan Chase & Co. dropped their target price on IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a report on Friday, February 6th. Jefferies Financial Group reduced their price target on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Finally, TD Cowen raised shares of IQVIA from a “hold” rating to a “buy” rating and boosted their price target for the company from $174.00 to $213.00 in a research report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $229.13.

IQVIA Trading Up 2.5%

Shares of IQVIA stock opened at $178.87 on Tuesday. The stock has a 50 day moving average of $206.26 and a 200 day moving average of $207.53. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75. The firm has a market capitalization of $30.35 billion, a price-to-earnings ratio of 22.76, a PEG ratio of 1.68 and a beta of 1.40. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $247.04.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, beating analysts’ consensus estimates of $3.40 by $0.02. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The company had revenue of $4.36 billion for the quarter, compared to the consensus estimate of $4.24 billion. During the same quarter in the previous year, the business earned $3.12 earnings per share. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.